Fusion Pharmaceuticals In... (FUSN)
NASDAQ: FUSN
· Real-Time Price · USD
21.55
0.03 (0.14%)
At close: Jun 03, 2024, 10:00 PM
Fusion Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 33.64M | 2.01M | 34K | 28K | 140K | 166K | 570K | 585K | 594K | 325K | 521K | n/a |
Cost of Revenue | 361K | 361K | 1.04M | 931K | 15.88M | 17.61M | 16.55M | 12.08M | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -361K | 33.27M | 962K | -897K | -15.85M | -17.47M | -16.39M | -11.51M | 585K | 594K | 325K | 521K | n/a |
Operating Income | -35.86M | -28.27M | -19.39M | -26.71M | -24.86M | -24.42M | -23.8M | -19.29M | -20.52M | -17.55M | -19.52M | -27.27M | -17.68M |
Interest Income | 3.51M | 2.29M | 2.82M | 2.5M | 1.92M | 1.31M | 190K | n/a | 83K | 81K | n/a | n/a | n/a |
Pretax Income | -33.91M | -26.88M | -17.5M | -25.42M | -24.3M | -24.96M | -24.77M | -19.75M | -19.96M | -17.41M | -19.38M | -26.84M | -17.54M |
Net Income | -33.67M | -28.18M | -17.25M | -25.18M | -24.29M | -24.62M | -24.01M | -19.07M | -19.91M | -17.24M | -19.43M | -26.85M | -17.53M |
Selling & General & Admin | 14.55M | 7.63M | 6.81M | 7.75M | 9.01M | 6.95M | 7.42M | 7.78M | 8.45M | 6.34M | 7.16M | 6.64M | 6.96M |
Research & Development | 20.95M | 20.29M | 14.59M | 18.99M | 15.88M | 17.61M | 16.55M | 12.08M | 12.66M | 11.81M | 12.68M | 21.15M | 10.72M |
Other Expenses | 297K | n/a | 391K | 80K | -145K | -680K | -1.16M | -414K | n/a | 63K | 27K | n/a | 48K |
Operating Expenses | 35.5M | 27.91M | 21.39M | 26.75M | 24.88M | 24.56M | 23.97M | 19.86M | 21.11M | 18.15M | 19.84M | 27.79M | 17.68M |
Interest Expense | 1.85M | 1.34M | 1.32M | 1.28M | 1.22M | 1.17M | 190K | n/a | 83K | 81K | 107K | 97K | 96K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 35.86M | 28.27M | 21.39M | 26.75M | 24.88M | 24.56M | 23.97M | 19.86M | 21.11M | 18.15M | 19.84M | 27.79M | 17.68M |
Income Tax Expense | -237K | 1.3M | -253K | -245K | -11K | -340K | -761K | -681K | -55K | -173K | 48K | 14K | -7K |
Shares Outstanding (Basic) | 83.78M | 73.09M | 69.05M | 66.28M | 53.78M | 44.77M | 43.68M | 43.36M | 43.17M | 43.07M | 43.02M | 42.5M | 41.78M |
Shares Outstanding (Diluted) | 83.78M | 73.09M | 69.05M | 66.28M | 53.78M | 44.77M | 43.68M | 43.36M | 43.17M | 43.07M | 43.02M | 42.5M | 41.78M |
EPS (Basic) | -0.4 | -0.39 | -0.25 | -0.38 | -0.45 | -0.55 | -0.55 | -0.44 | -0.46 | -0.4 | -0.45 | -0.63 | -0.42 |
EPS (Diluted) | -0.4 | -0.39 | -0.25 | -0.38 | -0.45 | -0.55 | -0.55 | -0.44 | -0.46 | -0.4 | -0.45 | -0.63 | -0.42 |
EBITDA | -35.5M | -27.91M | -19.39M | -23.8M | -23.08M | -23.79M | -23.56M | -19.07M | -20.32M | -17.55M | -19.33M | -27.11M | -17.57M |
EBIT | -32.05M | -25.55M | -18.83M | -24.14M | -23.08M | -23.79M | -24.58M | -19.81M | -19.88M | -17.33M | -19.27M | -26.74M | -17.44M |
Depreciation & Amortization | 361K | 361K | 374K | 337K | 1.78M | 629K | 242K | 216K | 203K | 184K | 185K | 154K | 111K |